Keywords: Hikma, Hubei Haosum, M&A, APIs, China
Hikma takes stake in China’s Hubei Haosun to enhance API sourcing
Article | 11 July 2011
Fast-growing Jordan-headquartered drugmaker Hikma Pharmaceuticals (LSE: HIK) says that it has acquired a “significant,” but undiscosed minority interest ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
